{
    "nct_id": "NCT03573700",
    "official_title": "SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia",
    "inclusion_criteria": "Inclusion Criteria for Autologous Apheresis:\n\n* Age ≤ 21 years old\n* CD19+ ALL with any of the following:\n\n  * Minimal Residual Disease (MRD) ≥ 1% at end of up-front induction therapy\n  * Hypodiploid (< 44 chromosomes or < 0.95 DNA index) CD19+ ALL with detectable disease at the end of up-front induction therapy\n  * Increase in disease burden any time after the completion of up-front induction therapy\n  * Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission\n  * Refractory disease despite salvage therapy\n  * 1st or greater relapse\n* Estimated life expectancy of > 12 weeks\n* Karnofsky or Lansky (age-dependent) performance score ≥ 50\n* Patients with a history of prior allogeneic hematopoietic cell transplantation [HCT] must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis\n* For females of child bearing age:\n\n  * Not lactating with intent to breastfeed\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n\nExclusion Criteria for Autologous Apheresis:\n\n* Known primary immunodeficiency\n* History of HIV infection\n* Severe intercurrent bacterial, viral or fungal infection\n* History of hypersensitivity reactions to murine protein-containing products\n\nEligibility Criteria for Manufacturing SJCAR19:\n\n* CD19+ ALL with any of the following:\n\n  * Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission\n  * Refractory disease despite salvage therapy\n  * 2nd or greater relapse\n  * Any relapse after allogeneic hematopoietic cell transplantation\n  * 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT\n* Age: ≤ 21 years of age\n* Karnofsky or Lansky (age-dependent) performance score ≥ 50\n* Estimated life expectancy of > 12 weeks\n* Meets eligibility criteria to undergo autologous apheresis, or have previously undergone autologous apheresis\n\nInclusion Criteria for Treatment with SJCAR19:\n\n* CD19+ ALL with any of the following:\n\n  * Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission\n  * Refractory disease despite salvage therapy\n  * 2nd or greater relapse\n  * Any relapse after allogeneic hematopoietic cell transplantation\n  * 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT for any of the following reasons:\n\n    * Patients that do not have an available allogeneic donor (defined as at least a 7/8 HLA-matched related/unrelated donor, 5/6 HLA-matched umbilical cord donor, or 3/6 HLA-matched haploidentical donor)\n    * Patients with refractory leukemia, for which allogeneic transplant is known to be less effective in the B-ALL population, and\n    * Patients who are unable to receive myeloablative total body irradiation (TBI), which is included in standard transplant regimens for patients with B - ALL.\n* Detectable disease\n* Age: ≤ 21 years of age\n* Estimated life expectancy of > 8 weeks\n* Prior to planned SJCAR19 infusion, patients with a history of prior allogeneic HCT must be at least 3 months from HCT, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion\n* Adequate cardiac function defined as left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%\n* EKG without evidence of clinically significant arrhythmia\n* Adequate renal function defined as creatinine clearance or radioisotope GFR ≥50 ml/min/1.73m2 (GFR ≥40 ml/min/1.73m2 if < 2 years of age)\n* Adequate pulmonary function defined as forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Karnofsky or Lansky (age-dependent) performance score ≥ 50\n* Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n* Hemoglobin > 8 g/dl (can be transfused)\n* Platelet count > 20,000/μL (can be transfused)\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For females of child bearing age:\n\n  * Not lactating with intent to breastfeed\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n  * If sexually active, agreement to use birth control until 6 months after T-cell infusion. Male partners should use a condom\n* Available SJCAR19 product with ≥ 15% expression of the CD19-CAR, and killing of CD19+ targets ≥ 20% in an in vitro cytotoxicity assay\n* Agreement to participate in long-term follow-up on protocol NCT00695279\n\nExclusion Criteria for Treatment with SJCAR19:\n\n* CNS-3 disease with or without neurologic changes\n* CNS-1/CNS-2 disease with neurologic changes\n* Known primary immunodeficiency\n* History of HIV infection\n* Evidence of active, uncontrolled neurologic disease\n* Severe, uncontrolled bacterial, viral or fungal infection\n* History of hypersensitivity reactions to murine protein-containing products\n* Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/ kg/day of methylprednisolone, in the 7 days prior to CAR T-cell infusion\n* Receiving systemic immunosuppressive therapy in the 14 days prior to CAR T-cell infusion\n* Receiving intrathecal chemotherapy in the 7 days prior to CAR T-cell infusion\nHealthy volunteers allowed\nMust have maximum age of 21 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}